Literature DB >> 17707509

Paratope diversity in the human antibody response to Bacillus anthracis protective antigen.

Jianhui Zhou1, Anuska Ullal, Justine Liberato, Jinying Sun, Wendy Keitel, Donald C Reason.   

Abstract

The active component of the licensed human anthrax vaccine (BioThrax, or AVA) is a Bacillus anthracis toxin known as protective antigen (PA). Second generation anthrax vaccines currently under development are also based on a recombinant form of PA. Since the current and future anthrax vaccines are based on this toxin, it is important that the immunobiology of this protein in vaccinated humans be understood in detail. We have isolated and analyzed the PA-specific antibody repertoire from an AVA-vaccinated individual. When examined at the clonal level, we find an antibody response that is complex in terms of the combinatorial elements and immunoglobulin variable genes employed. All PA-specific antibodies had undergone somatic hypermutation and class switch recombination, both signs of affinity maturation. Although the antigenic epitopes recognized by the response were distributed throughout the PA monomer, the majority of antibodies arising in this individual following vaccination recognize determinants located on the amino-terminal (PA20) sub-domain of the molecule. This latter finding may have implications for the rational design of future PA-based anthrax vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707509      PMCID: PMC2063455          DOI: 10.1016/j.molimm.2007.06.159

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  33 in total

1.  Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen.

Authors:  Kristina Cunningham; D Borden Lacy; Jeremy Mogridge; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

2.  Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F.

Authors:  Jianhui Zhou; Kathleen R Lottenbach; Stephen J Barenkamp; Alexander H Lucas; Donald C Reason
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

3.  IMGT, the international ImMunoGeneTics database.

Authors:  M P Lefranc; V Giudicelli; C Ginestoux; J Bodmer; W Müller; R Bontrop; M Lemaitre; A Malik; V Barbié; D Chaume
Journal:  Nucleic Acids Res       Date:  1999-01-01       Impact factor: 16.971

Review 4.  Somatic hypermutation of immunoglobulin genes.

Authors:  S D Wagner; M S Neuberger
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 5.  Molecular basis for improved anthrax vaccines.

Authors:  Robert N Brey
Journal:  Adv Drug Deliv Rev       Date:  2005-04-21       Impact factor: 15.470

6.  Role of toxin functional domains in anthrax pathogenesis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

7.  Human Fab fragments specific for the Haemophilus influenzae b polysaccharide isolated from a bacteriophage combinatorial library use variable region gene combinations and express an idiotype that mirrors in vivo expression.

Authors:  D C Reason; T C Wagner; A H Lucas
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

8.  Ig mu-epsilon isotype switch in IL-4-treated human B lymphoblastoid cells. Evidence for a sequential switch.

Authors:  F C Mills; G Thyphronitis; F D Finkelman; E E Max
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

9.  Correlation of antigenic epitope and antibody gene usage in the human immune response to Streptococcus pneumoniae type 23F capsular polysaccharide.

Authors:  Donald C Reason; Jianhui Zhou
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

10.  The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.

Authors:  F Matsuda; K Ishii; P Bourvagnet; K i Kuma; H Hayashida; T Miyata; T Honjo
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  5 in total

1.  Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.

Authors:  Rebecca A Brady; Anita Verma; Bruce D Meade; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

2.  Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.

Authors:  Kristin H Clement; Thomas L Rudge; Heather J Mayfield; Lena A Carlton; Arelis Hester; Nancy A Niemuth; Carol L Sabourin; April M Brys; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

3.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

4.  Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed.

Authors:  Donald Reason; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Infect Immun       Date:  2009-02-17       Impact factor: 3.441

5.  Mechanism of lethal toxin neutralization by a human monoclonal antibody specific for the PA(20) region of Bacillus anthracis protective antigen.

Authors:  Donald Reason; Justine Liberato; Jinying Sun; Jessica Camacho; Jianhui Zhou
Journal:  Toxins (Basel)       Date:  2011-08-09       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.